Drugs / EBV-specific T cells: B
EBV-specific T cells: B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01555892 | Jan 2013 → Mar 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific T cells: B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01555892 ↗ |
| Known as | EBVST | “EBV-specific T-cell (EBVST) infusions have shown promise in safety and clinical effectiveness in treating EBV-associated lymphomas” PMID 39908567 ↗ Apr 2025 |
| Known as | GRALE T cells | “These cells are called GRALE T cells.” NCT01555892 ↗ |
| Action | Deplete | “that have been trained to kill EBV infected cells” NCT01555892 ↗ |
| Modality | Cell therapy | “These cells are called GRALE T cells.” NCT01555892 ↗ |
| Route | Other | “The GRALE T cells will then be thawed and injected into the subject over 1-10 minutes.” NCT01555892 ↗ |